Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

HELE vs SKIN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HELE Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

HELE Overall Winner 6-Pillar Tally: HELE 5 – 1 SKIN Matrix Metrics: HELE 9 – 1 SKIN

As of Nov 16, 2026, Helen Of Troy Ltd (HELE) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HELE carries a Unified Composite Score of 31.0/100 (SELL) at $37.65 (11.5x Forward P/E, 5.5% operating margin), whereas SKIN carries 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin).

  • Composite vs. Pillar Nuance: While SKIN currently prints a higher short-term Unified Composite Score (34.1/100 SELL vs. HELE 31.0/100 SELL), HELE captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.5% vs. 2.4% operating margin) and revenue trajectory (+2.1% vs. -2.1% YoY).
  • Defensive Composite Rating Caution: Although HELE compares more favorably head-to-head, both HELE (31.0/100 SELL) and SKIN (34.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HELE vs SKIN
HELE NASDAQ Head-to-Head Winner
Helen Of Troy Ltd
Electric Housewares & Fans
$37.65
+0.88% 1D
Market Cap $872.9M
TTM Revenue $1.83B
Forward P/E 11.5x
Beta / 30D Vol 0.81β · 93% Vol
Unified Composite Score
31.0 / 100 SELL
Tech 50.0 Fund 29.0 Flow 54.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.7% over 20 days), RSI 71
RSI-14: 71.5 · SMA20: $32.91 · SMA50: $29.75
SKIN NASDAQ
The Beauty Health Company Class A Common Stock
Surgical & Medical Instruments & Apparatus
$15.05
-7.73% 1D
Market Cap $106.3M
TTM Revenue $289M
Forward P/E 106.4x
Beta / 30D Vol -14.22β · 192% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (314.8% over 20 days), RSI 67
RSI-14: 67.4 · SMA20: $12.50 · SMA50: $6.24

6-Pillar Scorecard Institutional Category Breakdown (HELE 5 – 1 SKIN)

Columns: Metric · HELE · SKIN
1. Valuation Multiples HELE
Forward P/E 11.5x 106.4x
Trailing P/E 9.2x 106.4x
PEG Ratio 0.97x 0.93x
EV / Revenue 0.9x 0.9x
2. Growth & Scale HELE
Revenue Growth (YoY) +2.1% -2.1%
Earnings Growth (YoY) +24.9% +0.0%
TTM Revenue (USD) $1.83B $289M
Market Cap $872.9M $106.3M
3. Profitability & Quality HELE
Gross Margin 45.8% 67.2%
Operating Margin 5.5% 2.4%
Net Profit Margin -5.4% -6.3%
Return on Equity (ROE) -11.2% -30.1%
4. Balance Sheet & Cash Flow HELE
Cash Generation (TTM) $147M $17M
Cash Flow Margin 8.1% 5.8%
Net Cash / Leverage $703M Net Debt (0.85x D/E) $161M Net Debt (6.61x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning HELE
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 33.7% (<1st %ile) 517.4% (100th %ile)
Put/Call OI Skew 0.04x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat SKIN
OpEx & R&D Intensity 40.3% of Rev ($736M) 64.8% of Rev ($187M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Household & Personal Products Operator Household & Personal Products Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HELE (9) vs SKIN (1)
Institutional Metric HELE SKIN Criterion Row Edge
Market Capitalization
Scale
$872.9M $106.3M Larger Scale HELE
Trailing P/E Ratio
Valuation
9.2x 106.4x Lower Multiple HELE
Forward P/E Ratio
Valuation
11.5x 106.4x Lower Multiple HELE
Revenue Growth (YoY)
Growth
+2.1% -2.1% Higher Growth HELE
Operating Margin (TTM)
Profitability
5.5% 2.4% Higher Margin HELE
Net Profit Margin
Profitability
-5.4% -6.3% Higher Margin HELE
Return on Equity (ROE)
Capital Efficiency
-11.2% -30.1% Higher ROE HELE
52-Week Range Position
Momentum
94% ($14–$39) 83% ($0–$18) Stronger Trend HELE
Beta / 30D Volatility
Risk Regime
0.81β · 93% Vol -14.22β · 192% Vol Lower Realized Risk HELE
Unified Institutional Score
Composite Signal
31.0 / 100 (SELL) 34.1 / 100 (SELL) Higher Composite SKIN
Trailing 12M Revenue (USD)
Operating Scale
$1.83B $289M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
45.8% 67.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.97x PEG · 0.9x EV/Rev 0.93x PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$147M ($703M Net Debt (0.85x D/E)) $17M ($161M Net Debt (6.61x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SKIN +12.65 pp
HELE: +29.87% · SKIN: +42.52%
3M Horizon SKIN +2377.33 pp
HELE: +31.0% · SKIN: +2408.33%
6M Horizon SKIN +2327.94 pp
HELE: +57.2% · SKIN: +2385.14%
1Y Horizon SKIN +960.26 pp
HELE: +97.43% · SKIN: +1057.69%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period HELE Revenue SKIN Revenue HELE Op. Margin SKIN Op. Margin Margin Leader
FY2019 $1.56B $170M 12.7% 8.1% HELE
FY2020 $1.71B $120M 10.4% -14.4% HELE
FY2021 $2.10B $260M 13.4% -15.4% HELE
FY2022 $2.22B $370M 12.3% -7.1% HELE
FY2023 $2.07B $400M 10.2% -32.9% HELE
FY2024 $2.01B $330M 13.0% -20.3% HELE
FY2025 $1.91B $300M 7.5% -6.9% HELE
FY2026 $1.79B N/A -43.8% N/A HELE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HELE BREAKOUT
108d in phase · OBV ACCUMULATION
Current IV 33.7%
IV Percentile <1st %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact HELE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SKIN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 517.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact SKIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HELE Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $872.9M market capitalization and 5.5% operating margin.
OpEx & R&D Reinvestment 40.3% of Rev ($736M)
90D Engineering Disclosures 0 Published
SKIN Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $106.3M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($187M)
90D Engineering Disclosures 0 Published

Investor FAQ HELE vs SKIN Key Questions & Quantitative Answers

As of Nov 16, 2026, Helen Of Troy Ltd (HELE) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HELE carries a Unified Composite Score of 31.0/100 (SELL) at $37.65 (11.5x Forward P/E, 5.5% operating margin), whereas SKIN carries 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin). Composite vs. Pillar Nuance: While SKIN currently prints a higher short-term Unified Composite Score (34.1/100 SELL vs. HELE 31.0/100 SELL), HELE captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.5% vs. 2.4% operating margin) and revenue trajectory (+2.1% vs. -2.1% YoY). Defensive Composite Rating Caution: Although HELE compares more favorably head-to-head, both HELE (31.0/100 SELL) and SKIN (34.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

HELE leads the Growth & Scale pillar: HELE posts +2.1% YoY revenue growth and +24.9% YoY earnings growth on $1.83B TTM revenue (45.8% gross margin, 5.5% operating margin), compared with SKIN at -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), HELE cumulative revenue shifted +14.7% while SKIN shifted +76.5%. In operating R&D and SG&A reinvestment, HELE deploys 40.3% of Rev ($736M) (0 90-day corporate R&D disclosures) versus 64.8% of Rev ($187M) (0 disclosures) for SKIN.

HELE screens cheaper on headline valuation multiples. HELE trades at 11.5x Forward P/E, 9.2x Trailing P/E, 0.97x PEG, and 0.9x EV/Revenue (8.1% FCF margin), whereas SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HELE (-11.2% ROE) versus SKIN (-30.1% ROE) capital efficiency.

In options market volatility and institutional positioning, HELE carries 33.7% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.81β · 93% Vol realized risk). By comparison, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.